DHX37是一种编码DExD/H-box RNA解旋酶家族成员的基因,它在多种生物学过程中发挥着重要作用。DExD/H-box RNA解旋酶是一类参与RNA代谢的酶,它们能够解开RNA的双链结构,参与RNA的合成、剪接、转运和降解等过程。DHX37在细胞内主要定位于细胞核,参与核糖体的生物合成,并在RNA的剪接、转运和降解等过程中发挥重要作用。
DHX37在免疫系统中具有重要作用。研究表明,DHX37可以抑制CD8 T细胞的效应功能、细胞因子产生和T细胞活化。DHX37缺失可以增强抗原特异性CD8 T细胞对三阴性乳腺癌的疗效。此外,DHX37还可以调节NF-κB信号通路,影响免疫细胞的活化和功能。
DHX37还与神经发育障碍有关。研究表明,DHX37基因的变异与神经发育障碍和智力障碍等疾病相关。DHX37基因的变异可以导致中枢神经系统功能障碍、椎骨异常和面容畸形等表型。DHX37基因的变异还可以影响其他组织和器官系统,包括眼睛、外耳、听力、心脏和肾脏等。
DHX37还与性别发育障碍有关。DHX37基因的变异与46,XY性别发育障碍有关,包括性腺发育不全和睾丸退化综合征等。DHX37基因的变异可以导致睾丸发育不良和睾丸退化,影响性别发育。
DHX37还与肝细胞癌有关。研究表明,DHX37在肝细胞癌中高表达,并且与不良预后相关。DHX37可以通过与PLRG1相互作用,调节cyclin D1的表达,促进肝细胞癌的进展。此外,DHX37还可以影响免疫细胞浸润,促进免疫耐受,进而影响肝细胞癌的预后。
综上所述,DHX37是一种编码DExD/H-box RNA解旋酶家族成员的基因,它在免疫、神经发育、性别发育和肝细胞癌等过程中发挥着重要作用。DHX37的变异与多种疾病相关,包括神经发育障碍、智力障碍、性别发育障碍和肝细胞癌等。DHX37的研究有助于深入理解RNA解旋酶在生物学过程中的功能和疾病发生机制,为疾病的治疗和预防提供新的思路和策略[1][2][3][4][5][6][7][8][9][10]。
参考文献:
1. Dong, Matthew B, Wang, Guangchuan, Chow, Ryan D, Herbst, Roy S, Chen, Sidi. . Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. In Cell, 178, 1189-1204.e23. doi:10.1016/j.cell.2019.07.044. https://pubmed.ncbi.nlm.nih.gov/31442407/
2. Paine, Ingrid, Posey, Jennifer E, Grochowski, Christopher M, Lyon, Gholson J, Lupski, James R. 2019. Paralog Studies Augment Gene Discovery: DDX and DHX Genes. In American journal of human genetics, 105, 302-316. doi:10.1016/j.ajhg.2019.06.001. https://pubmed.ncbi.nlm.nih.gov/31256877/
3. Karaca, Ender, Harel, Tamar, Pehlivan, Davut, Gibbs, Richard A, Lupski, James R. . Genes that Affect Brain Structure and Function Identified by Rare Variant Analyses of Mendelian Neurologic Disease. In Neuron, 88, 499-513. doi:10.1016/j.neuron.2015.09.048. https://pubmed.ncbi.nlm.nih.gov/26539891/
4. de Oliveira, Felipe Rodrigues, Guaragna, Mara Sanches, Maciel-Guerra, Andréa Trevas, Guerra-Junior, Gil, Fabbri-Scallet, Helena. 2023. DHX37 and the Implications in Disorders of Sex Development: An Update Review. In Hormone research in paediatrics, 97, 433-444. doi:10.1159/000535969. https://pubmed.ncbi.nlm.nih.gov/38142677/
5. Liu, Nanbin, Zhang, Hailong, Zhang, Chunli, Li, Zongfang, Tian, Hongwei. 2023. DHX37 Is a Promising Prognostic Biomarker and a Therapeutic Target for Immunotherapy and Chemotherapy in HCC. In Cancers, 15, . doi:10.3390/cancers15215228. https://pubmed.ncbi.nlm.nih.gov/37958405/
6. Liu, Zhen, Ye, Youqiong, Liu, Yizhe, Chen, Zhiao, He, Xianghuo. . RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1. In Cancer research, 82, 1937-1952. doi:10.1158/0008-5472.CAN-21-3038. https://pubmed.ncbi.nlm.nih.gov/35290436/
7. de Oliveira, Felipe Rodrigues, Mazzola, Taís Nitsch, de Mello, Maricilda Palandi, Guerra-Junior, Gil, Fabbri-Scallet, Helena. 2023. DHX37 and NR5A1 Variants Identified in Patients with 46,XY Partial Gonadal Dysgenesis. In Life (Basel, Switzerland), 13, . doi:10.3390/life13051093. https://pubmed.ncbi.nlm.nih.gov/37240737/
8. Jiang, Wei, Yu, Jing, Mao, Yu, Li, Jianan, Yang, Jiyun. . Identification and functional analysis of a rare variant of gene DHX37 in a patient with 46,XY disorders of sex development. In Molecular genetics & genomic medicine, 12, e2453. doi:10.1002/mgg3.2453. https://pubmed.ncbi.nlm.nih.gov/38769888/
9. Xu, Yanni, Jiang, Qiongchao, Liu, Hejun, Saw, Phei Er, Luo, Baoming. 2020. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration. In Journal of immunology research, 2020, 8835393. doi:10.1155/2020/8835393. https://pubmed.ncbi.nlm.nih.gov/33490290/
10. Yu, Bao-Fu, Dong, Li-Ping, Dai, Chuan-Chang, Wei, Jiao. 2023. Genetic variations in patient with Parry-Romberg syndrome. In Scientific reports, 13, 400. doi:10.1038/s41598-023-27597-1. https://pubmed.ncbi.nlm.nih.gov/36624141/